TMCnet News
BAX, PWRM, EEFT, MS, - DrStockPick.com Stocks to Watch!Power 3 Medical Products Inc. (OTC BB: PWRM) recently has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimer?s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept (Donepezil HCl, Pfizer ? NYSE: PFE), Exelon (Rivastigmine, Novartis ? NYSE: NVS), and Namenda (Memantine HCl, Forest Laboratories ? NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer?s disease patients, i.e., those individuals who possess the Alzheimer?s high-risk gene for Apolipoprotein E4 and those who do not possess the gene. PWRM?s NuroPro was originally indicated for diagnostics to determine whether or not a patient had Alzheimer?s disease. With these results, PWRM?s NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms. Euronet Worldwide, Inc. ("Euronet" or the ?Company?) (NASDAQ: EEFT) reported it will release second quarter 2010 earnings results prior to the market opening on Wednesday, July 28th, 2010. Euronet will hold a conference call the same day at 9:00 a.m. Eastern Time to discuss the results. Morgan Stanley (NYSE: MS) plans to announce its second quarter 2010 financial results on Wednesday, July 21, 2010 at approximately 8:00 a.m. (ET). A conference call to discuss the results will be held on Wednesday, July 21, 2010 at 11:00 a.m. (ET). Baxter International Inc. (NYSE: BAX) reported that the U.S. Food and Drug Administration (FDA) has issued its final order regarding the previously communicated recall of COLLEAGUE infusion pumps from the U.S. market. Baxter will offer replacement infusion pumps or refunds to owners of COLLEAGUE pumps and will execute the recall over the next two years to minimize disruption to patient care. ************************************************************** Sign up to receive FREE stock alerts from PennyOmega.com at http://www.PennyOmega.com/signup ************************************************************** THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer ) . Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB). As a community-building service, TMCnet allows user submitted content which is not always proofed by TMCnet editors. If you feel this entry is of inferior quality or wish to report it for some reason, please forward the URL to "webedit [AT] tmcnet [DOT] com" with your comments. |